76 related articles for article (PubMed ID: 11418393)
1. A cost analysis of positron emission tomography.
Keppler JS; Conti PS
AJR Am J Roentgenol; 2001 Jul; 177(1):31-40. PubMed ID: 11418393
[TBL] [Abstract][Full Text] [Related]
2. The cost of positron emission tomography in six United States Veterans Affairs hospitals and two academic medical centers.
Berger M; Gould MK; Barnett PG
AJR Am J Roentgenol; 2003 Aug; 181(2):359-65. PubMed ID: 12876011
[TBL] [Abstract][Full Text] [Related]
3. Activity-based costing evaluation of [18F]-fludeoxyglucose production.
Krug B; Van Zanten A; Pirson AS; Crott R; Vander Borght T
Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):80-8. PubMed ID: 17891498
[TBL] [Abstract][Full Text] [Related]
4. Marginal cost of operating a positron emission tomography center in a regulatory environment.
Chuck A; Jacobs P; Logus JW; St Hilaire D; Chmielowiec C; McEwan AJ
Int J Technol Assess Health Care; 2005; 21(4):442-51. PubMed ID: 16262966
[TBL] [Abstract][Full Text] [Related]
5. Cost analyses of positron emission tomography for clinical use.
Evens RG; Siegel BA; Welch MJ; Ter-Pogossian MM
AJR Am J Roentgenol; 1983 Nov; 141(5):1073-6. PubMed ID: 6605052
[TBL] [Abstract][Full Text] [Related]
6. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
Zanzonico P; Dauer L; St Germain J
Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
[TBL] [Abstract][Full Text] [Related]
7. Assessing short-term effects and costs at an early stage of innovation: the use of positron emission tomography on radiotherapy treatment decision making.
Remonnay R; Morelle M; Pommier P; Giammarile F; Carrère MO
Int J Technol Assess Health Care; 2008; 24(2):212-20. PubMed ID: 18400125
[TBL] [Abstract][Full Text] [Related]
8. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
Wang YT; Huang G
Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
[TBL] [Abstract][Full Text] [Related]
9. [Costs of F-18-FDG PET with a satellite concept: update].
Lottes G; Schober O
Nuklearmedizin; 2000; 39(3):72-6. PubMed ID: 10834194
[TBL] [Abstract][Full Text] [Related]
10. FDG PET reimbursement.
Bietendorf J
J Nucl Med Technol; 2004 Mar; 32(1):33-8. PubMed ID: 14990673
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography: a first-hand experience.
Traylor J
Radiol Manage; 2000; 22(1):41-7. PubMed ID: 10787761
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma.
Krug B; Crott R; Roch I; Lonneux M; Beguin C; Baurain JF; Pirson AS; Vander Borght T
Acta Oncol; 2010; 49(2):192-200. PubMed ID: 20059314
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography: a financial and operational analysis.
Conti PS; Keppler JS; Halls JM
AJR Am J Roentgenol; 1994 Jun; 162(6):1279-86. PubMed ID: 8191981
[TBL] [Abstract][Full Text] [Related]
16. Principles and clinical applications of positron emission tomography.
Gardner SF; Green JA; Bednarczyk EM; Farnett L; Miraldi F
Am J Hosp Pharm; 1992 Jun; 49(6):1499-506. PubMed ID: 1530002
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography (PET) in the staging of head neck cancer: comparison between PET and CT.
Bruschini P; Giorgetti A; Bruschini L; Nacci A; Volterrani D; Cosottini M; Ursino F; Mariani G; Fattori B
Acta Otorhinolaryngol Ital; 2003 Dec; 23(6):446-53. PubMed ID: 15198047
[TBL] [Abstract][Full Text] [Related]
18. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
19. Activity-based costing evaluation of a [(18)F]-fludeoxyglucose positron emission tomography study.
Krug B; Van Zanten A; Pirson AS; Crott R; Borght TV
Health Policy; 2009 Oct; 92(2-3):234-43. PubMed ID: 19446356
[TBL] [Abstract][Full Text] [Related]
20. Costs of F-18-FDG PET: experience with a satellite concept.
Lottes G; Gorschlüter P; Kuwert T; Adam D; Schober O
Nuklearmedizin; 1998 Aug; 37(5):159-64; discussion 165. PubMed ID: 9728342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
